{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:00:46Z","timestamp":1785513646257,"version":"3.56.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n, Spain","doi-asserted-by":"crossref","award":["PID2023-149093OB-I00"],"award-info":[{"award-number":["PID2023-149093OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n, Spain","doi-asserted-by":"crossref","award":["MCIU\/AEI\/10.13039\/501100011033\/FEDER"],"award-info":[{"award-number":["MCIU\/AEI\/10.13039\/501100011033\/FEDER"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003946","name":"European Society for Sexual Medicine","doi-asserted-by":"publisher","award":["RG-19-20"],"award-info":[{"award-number":["RG-19-20"]}],"id":[{"id":"10.13039\/501100003946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012986","name":"Universidad Francisco de Vitoria","doi-asserted-by":"publisher","award":["UFV2021-14"],"award-info":[{"award-number":["UFV2021-14"]}],"id":[{"id":"10.13039\/100012986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intraplaque injection of collagenase Clostridium histolyticum (CCH) is a therapeutic approach for treating Peyronie\u2019s disease (PD) that may represent an alternative to surgery in some patients. However, the efficacy of collagenase injection is rather variable among patients. Nanocapsules (NC) provide therapeutic advantages by allowing sustained protein release and preserving enzymatic activity. The aim was to evaluate the in vitro efficacy of preparation of polymeric NC containing collagenase in reducing human PD plaque.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Polymeric nanocapsules containing collagenase type I (ColNC) or blank NC were synthesized. Enzymatic activity of ColNC and free-collagenase (Col) was determined. The impact of NC, ColNC, and Col on cell viability of commercially available fibroblasts and myofibroblasts was determined. The effects of treatments on differentiation of fibroblasts obtained from plaques of PD patients into myofibroblast and differential cell viabilities were evaluated. Plaque tissues from PD patients (n\u2009=\u200913) were injected with phosphate-buffered saline solution, Col (0.1%), ColNC (0.1%), or equivalent amount of NC. Seven days after, the reduction in plaque tissue weight, type 1 collagen content, and the release of protein to the medium were determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nanocapsules exerted protective effect for collagenase by preserving its activity for 10\u00a0days versus 48\u00a0h for Col. Although fibroblasts from PD patients were unaffected, ColNC decreased the viability of myofibroblasts by 80% compared to 20% reduction obtained by Col. Single injection of ColNC into PD plaque reduced weight by 30%, compared to 10% by Col. This was related to significant reduction in collagen content in the plaque and increased protein content in the medium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Extending CCH activity and efficacy by nanoencapsulation may reduce injection repeats and improve therapeutic response to CCH injection, potentially representing a therapeutic strategy. Superiority of ColNC was demonstrated with biochemical assays, cell culture procedures, and in vitro functional evidence in plaque tissue from PD patients. Main limitation was the relatively low number of human samples due to limited human tissue availability. Encapsulation of collagenase into polymeric NC extends enzymatic activity and efficiency to degrade fibrous PD plaque. These results suggest that treatment with ColNC may represent a potential therapeutic strategy to reduce injection repeats in the management of PD but requires validation in in vivo and clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag231","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:58:58Z","timestamp":1783684738000},"source":"Crossref","is-referenced-by-count":0,"title":["Collagenase nanocapsules for the treatment of Peyronie\u2019s disease. Evaluation in fibrotic plaques obtained from human patients"],"prefix":"10.1093","volume":"23","author":[{"given":"Carla","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense de Madrid , 28040-Madrid ,","place":["Spain"]},{"name":"CIBER de Bioingenier\u00eda, Biomateriales y Nanomedicina, Instituto de Salud Carlos III , 28029-Madrid ,","place":["Spain"]},{"name":"Department of Health Science, School of Biomedical Sciences, Universidad Europea de Madrid , 28670-Villaviciosa de Od\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa\u00fa","family":"Fern\u00e1ndez-Pascual","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital La Paz , 28029-Madrid ,","place":["Spain"]},{"name":"Lyx Institute of Urology, Universidad Francisco de Vitoria , 28006-Madrid ,","place":["Spain"]},{"name":"Facultad de Medicina, Universidad Complutense de Madrid , 28040-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-9465","authenticated-orcid":false,"given":"Javier","family":"Angulo","sequence":"additional","affiliation":[{"name":"Servicio de Investigaci\u00f3n Histol\u00f3gica, Unidad de Investigaci\u00f3n Traslacional en Cardiolog\u00eda\u2014IRYCIS, Hospital Universitario Ram\u00f3n y Cajal , 28034-Madrid ,","place":["Spain"]},{"name":"CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III , 28029-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-5199","authenticated-orcid":false,"given":"F\u00e9lix","family":"Campos-Juanatey","sequence":"additional","affiliation":[{"name":"Andrology and Reconstructive Urology Unit, School of Medicine, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, IDIVAL , 38008-Santander ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Garc\u00eda-Baquero","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital Puerta del Mar , 11009-C\u00e1diz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Conde-Redondo","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital R\u00edo Hortega , 47012-Valladolid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1071-3656","authenticated-orcid":false,"given":"Borja","family":"Garc\u00eda-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital Doce de Octubre , 28041-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-7434","authenticated-orcid":false,"given":"Giuseppe","family":"Maiolino","sequence":"additional","affiliation":[{"name":"Lyx Institute of Urology, Universidad Francisco de Vitoria , 28006-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Pedro","family":"Palma-Hendges","sequence":"additional","affiliation":[{"name":"Lyx Institute of Urology, Universidad Francisco de Vitoria , 28006-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Lled\u00f3-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Lyx Institute of Urology, Universidad Francisco de Vitoria , 28006-Madrid ,","place":["Spain"]},{"name":"Facultad de Medicina, Universidad Complutense de Madrid , 28040-Madrid ,","place":["Spain"]},{"name":"Urology Department, General University Hospital Gregorio Mara\u00f1\u00f3n, Universidad Complutense de Madrid , 28007-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Arcos","sequence":"additional","affiliation":[{"name":"Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense de Madrid , 28040-Madrid ,","place":["Spain"]},{"name":"CIBER de Bioingenier\u00eda, Biomateriales y Nanomedicina, Instituto de Salud Carlos III , 28029-Madrid ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre i+12 , 28041-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Mart\u00ednez-Salamanca","sequence":"additional","affiliation":[{"name":"Lyx Institute of Urology, Universidad Francisco de Vitoria , 28006-Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026073111215414900_ref1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0022-5347(01)65359-X","article-title":"The anatomy of the tunica albuginea in the normal penis and Peyronie's disease","volume":"157","author":"Brock","year":"1997","journal-title":"J Urol"},{"key":"2026073111215414900_ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41443-019-0204-1","article-title":"Plication techniques in Peyronie's disease: new developments","volume":"32","author":"Garc\u00eda-G\u00f3mez","year":"2020","journal-title":"Int J Impot Res"},{"key":"2026073111215414900_ref3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"key":"2026073111215414900_ref4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/2090598X.2021.1957411","article-title":"Peyronie's disease\u2014outcomes of collagenase clostridium histolyticum injection: a systematic review","volume":"19","author":"Mefford","year":"2021","journal-title":"Arab J Urol"},{"key":"2026073111215414900_ref5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/01.ju.0000053800.62741.fe","article-title":"Peyronie's disease: a review","volume":"169","author":"Gholami","year":"2003","journal-title":"J Urol"},{"key":"2026073111215414900_ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ddmec.2004.06.002","article-title":"Mechanism,s of, and novel pharmacological approaches to, Peyronie\u2019s disease","volume":"1","author":"Gonzalez-Cadavid","year":"2004","journal-title":"Drug Discov Today Dis Mech"},{"key":"2026073111215414900_ref7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0022-5347(01)68236-3","article-title":"An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression","volume":"158","author":"El-Sakka","year":"1997","journal-title":"J Urol"},{"key":"2026073111215414900_ref8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1046\/j.1464-410x.2003.04224.x","article-title":"Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease","volume":"91","author":"Davila","year":"2003","journal-title":"BJU Int"},{"key":"2026073111215414900_ref9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/path.1427","article-title":"The myofibroblast in wound healing and fibrocontractive diseases","volume":"200","author":"Gabbiani","year":"2003","journal-title":"J Pathol"},{"key":"2026073111215414900_ref10","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.1999.277.1.C1","article-title":"Paracrine cells important in health and disease","volume":"277","author":"Powell","year":"1999","journal-title":"Am J Phys"},{"key":"2026073111215414900_ref11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1081\/jdi-100104736","article-title":"Myofibroblast: a prognostic marker and target cell in progressive renal disease","volume":"23","author":"Badid","year":"2001","journal-title":"Ren Fail"},{"key":"2026073111215414900_ref12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11926-002-0008-y","article-title":"Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis","volume":"4","author":"Kissin","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"2026073111215414900_ref13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/s1089-8603(02)00124-6","article-title":"Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model","volume":"7","author":"Vernet","year":"2002","journal-title":"Nitric Oxide"},{"key":"2026073111215414900_ref14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jsxm.2019.10.013","article-title":"Impact of the advent of collagenase Clostridium histolyticum on the surgical management of Peyronie's disease: a population-based analysis","volume":"17","author":"Mills","year":"2020","journal-title":"J Sex Med"},{"key":"2026073111215414900_ref15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/TCRM.S8591","article-title":"The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease","volume":"6","author":"Thomas","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"2026073111215414900_ref16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/bju.14784","article-title":"Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling","volume":"124","author":"Fern\u00e1ndez-Pascual","year":"2019","journal-title":"BJU Int"},{"issue":"2","key":"2026073111215414900_ref17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.sxmr.2017.07.011","article-title":"Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture","volume":"6","author":"Beilan","year":"2018","journal-title":"Sex Med Rev"},{"key":"2026073111215414900_ref18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.urology.2023.10.019","article-title":"Risk factors for penile fracture after intralesional collagenase Clostridium histolyticum in Peyronie's disease","volume":"183","author":"Zucker","year":"2024","journal-title":"Urology."},{"issue":"194","key":"2026073111215414900_ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2014.08.015","article-title":"Stimuli-responsive nanomaterials for therapeutic protein delivery","volume":"194","author":"Lu","year":"2014","journal-title":"J Control Release"},{"key":"2026073111215414900_ref20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.actbio.2018.05.007","article-title":"Collagenase nanocapsules: an approach to fibrosis treatment","volume":"74","author":"Villegas","year":"2018","journal-title":"Acta Biomater"},{"key":"2026073111215414900_ref21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF01665905","article-title":"An improved method of establishing human fibroblast cultures from explants","volume":"6","author":"Cheung","year":"1980","journal-title":"J Tissue Culture Methods"},{"key":"2026073111215414900_ref22","doi-asserted-by":"publisher","first-page":"e13669","DOI":"10.14814\/phy2.13669","article-title":"Molecular changes during TGF\u03b2-mediated lung fibroblast-myofibroblast differentiation: implication for glucocorticoid resistance","volume":"6","author":"Breton","year":"2018","journal-title":"Physiol Rep"},{"key":"2026073111215414900_ref23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/pharmaceutics14020359","article-title":"Poly(lactic acid)-based microparticles for drug delivery applications: an overview of recent advances","volume":"14","author":"Vlachopoulos","year":"2022","journal-title":"Pharmaceutics."},{"key":"2026073111215414900_ref24","doi-asserted-by":"publisher","first-page":"10133","DOI":"10.3390\/ijms241210133","article-title":"Molecular mechanisms and risk factors related to the pathogenesis of Peyronie's disease","volume":"24","author":"Mitsui","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026073111215414900_ref25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","article-title":"Latent TGF-\u03b2 structure and activation","volume":"474","author":"Shi","year":"2011","journal-title":"Nature."},{"key":"2026073111215414900_ref26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"key":"2026073111215414900_ref27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.fmre.2021.11.033","article-title":"Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts","volume":"2","author":"He","year":"2021","journal-title":"Fundam Res"},{"key":"2026073111215414900_ref28","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1016\/j.biomaterials.2006.04.005","article-title":"Dense fibrillar collagen matrices: a model to study myofibroblast behaviour during wound healing","volume":"27","author":"Helary","year":"2006","journal-title":"Biomaterials."},{"key":"2026073111215414900_ref29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41443-023-00742-0","article-title":"In vitro efficacy of intralesional collagenase Clostridium histolyticum for the treatment of calcified Peyronie's disease plaques","volume":"36","author":"Dullea","year":"2024","journal-title":"Int J Impot Res"},{"key":"2026073111215414900_ref30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cdtm.2020.06.001","article-title":"New insights into the pathogenesis of Peyronie's disease: a narrative review","volume":"6","author":"Krakhotkin","year":"2020","journal-title":"Chronic Dis Transl Med"},{"key":"2026073111215414900_ref31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/UPJ.0000000000000696","article-title":"Long-term satisfaction with collagenase clostridium histolyticum for Peyronie's disease: clinical predictors and side effect profile","volume":"12","author":"Song","year":"2025","journal-title":"Urol Pract"},{"key":"2026073111215414900_ref32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/JU.0000000000003634","article-title":"Comparison of collagenase clostridium histolyticum to surgery for the management of Peyronie's disease: a randomized trial","volume":"210","author":"Green","year":"2023","journal-title":"J Urol"},{"key":"2026073111215414900_ref33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.urology.2023.10.022","article-title":"The discontinuation rate with collagenase clostridium histolyticum for Peyronie's disease in a high-volume practice is unexpectedly high: identifying opportunities for patient care improvement","volume":"183","author":"Lehner","year":"2024","journal-title":"Urology."},{"key":"2026073111215414900_ref34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2023.02.019","article-title":"Incremental treatment response by cycle with collagenase clostridium histolyticum for Peyronie's disease: a pooled analysis of two phase 3 trials","volume":"175","author":"Ziegelmann","year":"2023","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/8\/qdag231\/70412721\/qdag231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/8\/qdag231\/70412721\/qdag231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:21:59Z","timestamp":1785511319000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag231\/8748463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag231","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,3]]},"article-number":"qdag231"}}